NEW YORK – Wall Street analysts took a mixed view of Myriad Genetics today following the announcement on Friday by the US Supreme Court that it would review a lawsuit challenging the company’s patents related to the BRCA1 and BRCA2 genes.
View the original article here: Analysts Provide Mixed Views on Myriad After Supreme Court Agrees to Rehear Patent Case